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Introduction: Poisoning is an increasingly important cause of injury in the United States. In 2009 
poison centers received 2,479,355 exposure reports, underscoring the role of poison centers in 
intentional and unintentional injury prevention. Antiretroviral (ARV) agents are commonly prescribed 
drugs known to cause toxicity, yet the frequency of these incidents is unknown. The objectives of this 
study were to quantify the number of reported cases of toxicity secondary to ARV agents at a regional 
poison center, and to describe the circumstances and clinical manifestations of these poisonings. 
Methods: We conducted a retrospective review of poison center records between December 1, 
2001, and January 7, 2010.
Results: One hundred sixty-two exposures to ARV agents were reported to the poison center, of 
which 30% were intentional and 70% were unintentional. Three patients developed major toxicity 
and no deaths occurred. The remaining patients developed moderate and minor effects as defined 
by poison center guidelines.
Conclusion: ARV drug toxicity appears to be infrequently reported to the poison center. Fatal 
and major toxicities are uncommon, and intentional overdoses are associated with a more 
serious toxicity. Educational efforts should encourage clinicians to report toxicities related to the 
use of ARV agents to poison centers in order to better study this problem. [West J Emerg Med. 
2011;12(3):293-295.]
INTRODUCTION
Poisoning, an important cause of morbidity and mortality 
in the United States (U.S.), can be intentional or unintentional. 
Poison centers receive reports from the public, as well as 
healthcare professionals, for poisoning exposures in the 50 
states and U.S. territories.1 The data is compiled and 
monitored in a near-real time setting through the National 
Poison Data System.2
Antiretroviral agents (ARVs) are commonly prescribed 
drugs with well-characterized adverse effects. They are 
effective in improving survival rates for patients with human 
immunodeficiency virus and acquired immunodeficiency 
syndrome.3  However, chronic adverse effects, such as 
pancreatitis, hypersensitivity, peripheral neuropathy and 
nephrolithiasis, can limit clinical effectiveness and in some 
cases may be fatal. Lactic acidosis is the most serious adverse 
effect. It can be seen in the setting of acute overdose, as well 
as with chronic therapeutic use, and has a mortality of 33-
57%.4 
The true incidence of intentional or unintentional injury 
due to ARVs is unknown. A total of 5,563 exposures to ARVs 
were reported to the American Association of Poison Control 
Centers between 2001 and 2008, of which 29% were 
intentional. Five deaths were reported and 4% of patients had 
major clinical outcomes.2
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and unintentional injuries due to toxic exposures to ARV 
medications reported to the Georgia Poison Center (GPC).
METHODS
The GPC is located in Atlanta and serves the state of 
Georgia. It receives more than 80,000 exposure calls per year 
and has one of the largest call volumes when compared to the 
rest of the nation’s poison centers. Specialists in Poison 
Information Systems (SPIS) answer all incoming calls from 
both persons in the community and medical professionals. 
Their tasks are to record pertinent information about the 
poisoning and make recommendations regarding management. 
The patient’s name, age and gender are recorded, as well the 
names of all substances involved, amount, route, 
circumstances, time of exposure and symptoms. These data 
are entered into the poison center database using a 
combination of specific data fields and free text space.  
Based on information from the initial phone call, the SPIS 
classify clinical outcome due to the exposure as a no effect, 
minor, moderate, major outcome or death. Case outcomes are 
classified as minor when the effect involves only one organ 
system, is short in duration and has no permanent effects. 
Effects that are more prolonged (as judged by the SPIS) or 
involve more than one organ system are termed moderate 
outcomes. Major outcomes involve permanent disability or 
life-threatening exposures. Exposures that do not meet these 
criteria are deemed to have no potential to be toxic, or not 
related to the reported clinical effect, and are not followed to 
an outcome. 
The poison center attempts to follow all exposures 
involving minor, moderate or major effects to outcome via 
phone calls to the patient or treating facility. Any additional 
information obtained from these phone calls is entered into the 
poison center database in the same fashion as the initial call. 
Occasionally, the poison center is unable to obtain further 
information about the case.  
Two study investigators accessed the poison center 
database in July 2009, and January 2010.  They queried for 
entries involving any ARV agent from December 1, 2001, 
through the date accessed, most recently, January 7, 2010. 
Information obtained for each case included patient age, 
gender, substances ingested, effects, therapies administered, 
management site and medical outcome (when available). We 
performed descriptive statistics on demographics, type of 
medication and category of outcome after overdose. The local 
institutional review committee approved this study.
RESULTS
One hundred sixty-two exposures were documented 
between December 1, 2001 and January 7, 2010, with 15 
patients lost to follow up. The average patient age was 
27-years-old (standard deviation [SD] 19 years) and 100 cases 
(62%) were male. Zidovudine was the most common single 
drug reported as causing toxicity. It was involved in 46 
patients as a single or combination drug. 
Of the 162 exposures, 49 (30%) were judged intentional 
and 113 (70%) unintentional or unknown. We classified 
intentional exposures as suspected suicide (96%) or 
intentional misuse (4%). Unintentional exposures were 
classified as therapeutic error (58%), general unintentional 
(33%), adverse drug reactions (8%) or unknown (1%). 
General unintentional exposures are those not otherwise 
categorized as adverse drug reaction, therapeutic error, or 
unknown.
Of the 162 patients, 51 (31%) were categorized as 
potentially toxic or related to the clinical effect and were 
followed to clinical outcome. Thirty-four (67%) of these 
patients had intentional exposures. Of the 51 patients that were 
followed to a clinical outcome, 6% had a major, 27% had a 
moderate, 23% had a minor, and 51% had no effect. There 
were no patient deaths. Table 1 summarizes the above 
findings.
The three patients who had a major effect were admitted 
to a critical care unit. Two of these cases were reported as 
intentional ingestions and the third was an unknown exposure. 
One exposure involved Trizivir® which contains abacavir, 
lamivudine and zidovudine. This patient developed coma. A 
second exposure was to lamivudine (Epivir®) 300mg tablets, 
efavirenz (Sustiva®) 200mg capsules and abacavir (Ziagen®) 
300 mg tablets. This patient developed lactic acidosis, renal 
failure and coma. The final case with major toxicity involved 
exposure to stavudine alone. This patient developed renal 
Table 1. Clinical outcomes for intentional and unintentional exposures of antiretrovirals.
Clinical outcome Intentional exposures (n=49) Unintentional exposures (n=113)
Followed to outcome - major effect 2 1
Followed to outcome - moderate effect 10 4
Followed to outcome - minor effect 9 4
Followed to outcome - no effect 13 8
Not followed – nontoxic or not related to an effect 5 91
Unable to follow 10 5
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failure and coma. The number of pills ingested and non-ARV 
co-ingestants were not reported to the GPC for these cases. 
Among patients categorized with moderate effects, six 
reported exposure to multiple ARVs. Six patients were 
admitted to critical care units, three to psychiatric facilities, 
and the others required minimal medical treatment. The most 
common effects reported in this group were hypertension (six 
patients), tachycardia (four patients), agitation (three patients), 
hypotension (three patients) and vomiting (three patients).   
Thirteen patients were reported to have minor effects. One 
patient had a three-drug exposure and four patients had a 
two-drug exposure. The most common effects reported in this 
group were drowsiness or lethargy (four patients), abdominal 
pain (three patients) and vomiting (three patients).
Excluding the 15 patients that were lost to follow up, 54% 
of the intentional exposures had a major, moderate, or minor 
effect. This is in comparison to 8% of unintentional exposures.
DISCUSSION
Overall, exposures to ARVs comprise a small percent of 
the annual exposures reported to the GPC. There is no 
discernable trend in the number of exposures reported per year 
(Figure 1). There were a small number of cases of toxicity 
from ARV medications reported as well. Furthermore, only a 
small percentage of the total reported cases (2% or three 
patients) led to major toxicity. Due to our low numbers of 
critically ill patients, we are unable to predict which patients 
are at risk for severe morbidity or mortality. Based on our 
data, the majority of exposures to ARVs, whether intentional 
or unintentional, led to self-limited or no clinical effects.
As reported above, 54% of patients with intentional 
exposures had clinical effects, compared with 8% of patients 
with unintentional exposures. This results from larger doses of 
medications ingested by patients with intentional exposures 
compared to those who have adverse reactions due to 
therapeutic usage. Unfortunately, information on ingested dose 
is not consistently available.
In 2008, 60 U.S. Poison Centers reported receiving 
4,333,012 exposure calls from the public or health care 
providers.2 Although ARVs represent a small proportion 
of the reported exposures, the potential for serious injury 
due to these agents remains and is a public health concern. 
Clinicians should be encouraged to report all injuries 
due to pharmaceuticals to poison centers. This will help 
organizations, such as the AAPC, to construct less subjective 
data-collection tools. This could lead to more sensitive 
monitoring of trends of side effects of specific therapeutic 
agents or the use of certain pharmaceuticals, such as ARVs, for 
intentional injury. In this current era of preventive medicine 
and drug safety, a comprehensive, and rigorous, real-time 
surveillance system will prove invaluable to healthcare and 
public health. Policy makers and pharmaceutical companies 
can then use this information to minimize risks posed to 
patients by these drugs.
LIMITATIONS
There are several limitations to this study. First, it was 
a retrospective analysis of relatively few cases.  Cases of 
ARV toxicity may have been misclassified as an unknown 
ingestion. Poison center data have been shown to be prone 
to incompleteness and inaccuracy. Second, some of the 
compounds involved in exposures reported to the GPC have 
been introduced within the last 10 years, meaning less data 
exist on toxicities due to intentional or unintentional overdose 
for these compounds in the clinical setting. Furthermore, 
with fewer than 10 exposures reported for many of these 
compounds, drawing a link between exposure and outcomes 
is not possible. Moreover, the reported dose ingested is often 
unknown or uncertain. Lastly, we had 15 patients lost to 
follow-up.
CONCLUSION
Major toxicity and death due to ARV medication are rare 
occurrences, as currently reported to the GPC. Patients with 
intentional exposures were more likely to have clinical effects 
than patients with unintentional exposures. Clinicians should 
be encouraged to report suspected intentional or unintentional 
injury due to pharmaceuticals to their local poison center. 
In the future, policy makers can mandate reporting injuries 
by healthcare professionals from commonly used and or 
potentially toxic medications and greatly enhance the accuracy 
of existing surveillance systems.
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